Date | Title | Description | |
---|---|---|---|
12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
Pages
Date | Title | Description | |
---|---|---|---|
29 Dec 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 22 December and 28 December 2023 | Download |
22 Dec 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 15 December and 21 December 2023 | Download |
15 Dec 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 11 December and 14 December 2023 | Download |
11 Dec 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 1 December and 8 December 2023 | Download |
01 Dec 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 24 November and 30 November 2023 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
10 May 2018 | Otros sobre negocio y situación financiera | Update pivotal PRISMA-3 study of DORIA® (Risperidone ISM®) | Download |
25 Apr 2018 | Información sobre resultados | ROVI releases the press release related to the 2018 first quarter financial results | Download |
25 Apr 2018 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI informs about the call for the 2018 Ordinary General Shareholders Meeting | Download |
25 Apr 2018 | Información sobre resultados | ROVI releases the 2018 first quarter results presentation | Download |
04 Apr 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2018 | Download |